 |
 |
 |
 |
 |
 |
 |
Presentations on the Mechanism of Action of VEGFb™, the World’s only “Angiogenesis Modulator,” Support VEGFb’s Role as a Promising Treatment for Solid Cancers, Macular Degeneration, and Other Diseases
PhiloGene, Inc. Announces that VEGFbTM has been Granted Orphan Drug Designation by the FDA for the Treatment of Advanced Melanoma
PhiloGene Inc. Announces Revolutionary Advances in the Treatment of Cancer and Macular Degeneration BIO National Venture Conference 2008
University of Bristol Secures Multi-Million Deal for Natural Cancer Drug
PPS and PhiloGene Announce Collaboration to Develop and Manufacture PLG101 and PLG201
Coming Soon...
